Jazz Pharmaceuticals’ (JAZZ) Overweight Rating Reaffirmed at Piper Sandler
Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report released on Wednesday morning,Benzinga reports. The firm currently has a $176.00 price objective on the specialty pharmaceutical company’s stock, up from their previous price objective of $163.00. Several other equities research analysts have also issued reports on […]
Piper Sandler reaffirmed their overweight rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a report released on Wednesday morning,Benzinga reports. The firm currently has a $176.00 price objective on the specialty pharmaceutical company’s stock, up from their previous price objective of $163.00. Several other equities research analysts have also issued reports on […]
-logo-1200x675.png?v=20230920074015&w=240&h=240&zc=2){kind=logo}
